Vnitr Lek 2016, 62(10):795-803

The benefit of magnetic resonance for diagnosing cardiomyopathy and myocarditis

Michal Fikrle1,2, Petr Kuchynka2, Martin Mašek3, Jana Podzimková2, Jan Kuchař2, Aleš Linhart2, Tomáš Paleček2,*
1 Kardiologické oddělení Nemocnice Jihlava
2 II. interní klinika - klinika kardiologie a angiologie 1. LF UK a VFN v Praze
3 Radiodiagnostická klinika 1. LF UK a VFN v Praze

Magnetic resonance is becoming an increasingly used examination in cardiology, since it greatly improves the accuracy of diagnosing of many heart diseases. At present magnetic resonance is the gold standard in assessing the volumes of the heart chambers and the systolic function of both ventricles. The possibility of detecting tissue characteristics to refine the diagnostics of different types of myocardial pathology is of essential importance. The authors summarize in the article the present knowledge about the use of magnetic resonance of the heart in the field of myocardial disease, i.e. cardiomyopathy and myocarditis. The first part of the review gives a general introduction into the topic of magnetic resonance examination of myocardial diseases, which is followed by a detailed description of the benefits of this imaging method in dilated cardiomyopathy and myocarditis,in hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy.

Keywords: fibrosis; cardiomyopathy; magnetic resonance; myocarditis; late contrast agent saturation

Received: June 19, 2016; Accepted: August 1, 2016; Published: October 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fikrle M, Kuchynka P, Mašek M, Podzimková J, Kuchař J, Linhart A, Paleček T. The benefit of magnetic resonance for diagnosing cardiomyopathy and myocarditis. Vnitr Lek. 2016;62(10):795-803.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kim YJ, Kim RJ. The Role of Cardiac MR in New-Onset Heart Failure. Curr Cardiol Rep 2011; 13(3): 185-193. Go to original source... Go to PubMed...
    2. Mahrholdt H, Wagner A, Judd RM et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005; 26(15): 1461-1474. Go to original source... Go to PubMed...
    3. Maestrini V, Treibel TA, White SK et al. T1 Mapping for Characterization of Intracellular and Extracellular Myocardial Diseases in Heart Failure. Curr Cardiovasc Imaging Rep 2014; 7: 9287. Dostupné z DOI: <http://dx.doi.org/10.1007/s12410-014-9287-8>. Go to original source... Go to PubMed...
    4. Bohnen S, Radunski UK, Lund GK et al. Performance of T1 and T2 Mapping Cardiovascular Magnetic Resonance to Detect Active Myocarditis in Patients With Recent-Onset Heart Failure. Circ Cardiovasc Imaging 2015; 8(6): pii: e003073. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.114.003073>. Go to original source... Go to PubMed...
    5. Strohm O, Schulz-Menger J, Pilz B et al. Measurement of left ventricular dimensions and function in patients with dilated cardiomyopathy. J Magn Reson Imaging 2001; 13(3): 367-371. Go to original source... Go to PubMed...
    6. Karamitsos TD, Francis JM, Neubauer S. The Current and Emerging Role of Cardiovascular Magnetic Resonance in the Diagnosis of Nonischemic Cardiomyopathies. Prog Cardiovasc Dis 2011; 54(3): 253-265. Go to original source... Go to PubMed...
    7. Puntmann VO, Voigt T, Chen Z et al. Native T1 Mapping in Differentiation of Normal Myocardium from Diffuse Disease in Hypertrophic and Dilated Cardiomyopathy. JACC Cardiovasc Imaging 2013; 6(4): 475-484. Go to original source... Go to PubMed...
    8. Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Herat J. 2013; 34(33): 2636-2648. Go to original source... Go to PubMed...
    9. Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper. JACC 2009; 53(17): 1475-1487. Go to original source... Go to PubMed...
    10. Francone M, Chimenti C, Galea N et al. CMR Sensitivity Varies With Clinical Presentation and Extent of Cell Necrosis in Biopsy-Proven Acute Myocarditis. JACC Cardiovasc Imaging 2014; 7(3): 254-263. Go to original source... Go to PubMed...
    11. Vermes E, Childs H, Faris P et al. Predictive value of CMR criteria for LV functional improvement in patients with acute myocarditis. Eur Heart J Cardiovasc Imaging 2014; 15(10): 1140-1144. Go to original source... Go to PubMed...
    12. Elliot PM, Anastasakis A, Borger MA et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35(39): 2733-2779. Go to original source... Go to PubMed...
    13. Shehata ML, Turkbey EB, Vogel-Claussen J et al. Role of Cardiac Magnetic Resonance Imaging in Assessment of Nonischemic Cardiomyopathies. Top Magn Reson Imag 2008; 19(1): 43-57. Go to original source... Go to PubMed...
    14. Germans T, Wilde AA, Dijkmans PA et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006; 48(12): 2518-2523. Go to original source... Go to PubMed...
    15. Moon JC, Mogensen J, Elliott PM et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005; 91(8): 1036-1040. Go to original source... Go to PubMed...
    16. Moon JC, McKenna WJ, McCrohon JA et al. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41(9): 1561. Go to original source... Go to PubMed...
    17. Green JJ, Berger JS, Kramer CM et al. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012; 5(4): 370-377. Go to original source... Go to PubMed...
    18. Hinojar R, Varma N, Child N et al. T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging 2015; 8(12). pii: e003285. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCIMAGING.115.003285>. Go to original source... Go to PubMed...
    19. McNally E, MacLeold H, Dellefave-Castillo L. Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. In: Pagon RA, Adam MP, Ardinge HH et al. GeneReviews [Internet]. University of Washington: 1993-2016. 2005 [updated 2014]. Dostupné z WWW: <https://www.ncbi.nlm.nih.gov/books/NBK1131/>
    20. Sen-Chowdhry S, Syrris P, Prasat SK et al. Left-Dominant Arrhythmogenic Cardiomyopathy. J Am Coll Cardiol 2008; 52(25): 2175-2187. Go to original source... Go to PubMed...
    21. Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circulation 2010; 121(13): 1533-1541. Go to original source... Go to PubMed...
    22. Sen-Chowdhry S, Morgan RD, Chambers JC et al. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med 2010; 61: 233-253. Dostupné z DOI: <http://dx.doi.org/10.1146/annurev.med.052208.130419>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.